应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
VTRS Viatris Inc.
休市中 07-19 16:00:00 EDT
11.84
+0.07
+0.59%
盘后
11.84
+0.00
0.00%
19:46 EDT
最高
11.87
最低
11.65
成交量
550.03万
今开
11.85
昨收
11.77
日振幅
1.87%
总市值
140.98亿
流通市值
140.38亿
总股本
11.91亿
成交额
6,492万
换手率
0.46%
流通股本
11.86亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
晖致2024财年第一财季实现净利润1.14亿美元,同比减少49.33%
自选股智能写手 · 05-19
晖致2024财年第一财季实现净利润1.14亿美元,同比减少49.33%
BUZZ-Viatris 第一季度收入不及预期,业绩下滑
Reuters · 05-09
BUZZ-Viatris 第一季度收入不及预期,业绩下滑
晖致盘中异动 股价大跌5.76%
自选股智能写手 · 05-09
晖致盘中异动 股价大跌5.76%
Viatris Inc 预计每股收益 67 美分 - 财报前瞻
Reuters · 05-08
Viatris Inc 预计每股收益 67 美分 - 财报前瞻
英国 Theramex 公司认为 CMA 调查不会影响 HRT 产品供应
Reuters · 04-06
英国 Theramex 公司认为 CMA 调查不会影响 HRT 产品供应
英国监管机构称 Theramex-Viatris 交易引发竞争问题
Reuters · 04-04
英国监管机构称 Theramex-Viatris 交易引发竞争问题
BUZZ-杰富瑞认为澳大利亚 CSL 公司每股收益下降
Reuters · 03-26
BUZZ-杰富瑞认为澳大利亚 CSL 公司每股收益下降
嗡嗡声--美国股票走势-Acelyrin、Endeavour Silver、B2Gold
Reuters · 03-12
嗡嗡声--美国股票走势-Acelyrin、Endeavour Silver、B2Gold
美国 FDA 拒绝批准 Viatris 用于治疗多发性硬化症的注射剂
Reuters · 03-11
美国 FDA 拒绝批准 Viatris 用于治疗多发性硬化症的注射剂
Viatris Inc.2023财年实现净利润54.70百万美元,同比减少97.37%
自选股智能写手 · 03-04
Viatris Inc.2023财年实现净利润54.70百万美元,同比减少97.37%
嗡嗡声--美国股票走势-Shift4 Payments、Chart Industries、Applied Therapeutics
Reuters · 02-29
嗡嗡声--美国股票走势-Shift4 Payments、Chart Industries、Applied Therapeutics
Viatris Inc盘中异动 临近午盘急速下挫5.06%报12.56美元
自选股智能写手 · 02-29
Viatris Inc盘中异动 临近午盘急速下挫5.06%报12.56美元
BUZZ-Viatris 因第四季度业绩疲软而下跌
Reuters · 02-28
BUZZ-Viatris 因第四季度业绩疲软而下跌
Viatris Inc 预计每股收益 65 美分 - 财报前瞻
Reuters · 02-26
Viatris Inc 预计每股收益 65 美分 - 财报前瞻
Viatris Inc盘中异动 早盘股价大涨5.10%
自选股智能写手 · 02-15
Viatris Inc盘中异动 早盘股价大涨5.10%
暂无数据
公司概况
公司名称:
Viatris Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
Viatris Inc.于2019年2月14日在特拉华州成立。该公司是一家全球性的医疗保健公司,该公司认为他们具有独特的定位,可以弥合仿制药和品牌之间的传统鸿沟,将两者的优点结合起来,以更全面地满足全球范围内的医疗保健需求。Viatris的使命是赋能世界各地的人们在生命的每个阶段都能过上更健康的生活,它大规模地提供准入服务,目前每年为全球约10亿患者提供高质量的药物,并触及生命的所有时刻,从出生到生命的尽头,从急性病到慢性病。
发行价格:
--
{"stockData":{"symbol":"VTRS","market":"US","secType":"STK","nameCN":"Viatris Inc.","latestPrice":11.84,"timestamp":1721419200000,"preClose":11.77,"halted":0,"volume":5500279,"hourTrading":{"tag":"盘后","latestPrice":11.84,"preClose":11.84,"latestTime":"19:46 EDT","volume":159801,"amount":1891925.035,"timestamp":1721432810724},"delay":0,"floatShares":1185680457,"shares":1190675819,"eps":-0.04995,"marketStatus":"休市中","marketStatusCode":7,"change":0.07,"latestTime":"07-19 16:00:00 EDT","open":11.85,"high":11.87,"low":11.65,"amount":64920112.053182,"amplitude":0.018692,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.04995,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1721635200000},"adr":0,"listingDate":1605157200000,"adjPreClose":11.77,"dividendRate":0.040541,"preHourTrading":{"tag":"盘前","latestPrice":11.85,"preClose":11.77,"latestTime":"09:29 EDT","volume":575,"amount":6820.700025,"timestamp":1721395799999},"postHourTrading":{"tag":"盘后","latestPrice":11.84,"preClose":11.84,"latestTime":"19:46 EDT","volume":159801,"amount":1891925.035,"timestamp":1721432810724},"volumeRatio":0.6951322710378978,"impliedVol":0.3758,"impliedVolPercentile":0.881},"requestUrl":"/m/hq/s/VTRS/tweets","defaultTab":"tweets","newsList":[{"id":"2436518904","title":"晖致2024财年第一财季实现净利润1.14亿美元,同比减少49.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2436518904","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2436518904?lang=zh_cn&edition=full","pubTime":"2024-05-19 00:12","pubTimestamp":1716048721,"startTime":"0","endTime":"0","summary":"3月31日,晖致公布财报,公告显示公司2024财年第一财季净利润为1.14亿美元,同比减少49.33%;其中营业收入为36.57亿美元,同比减少1.69%,每股基本收益为0.10美元。通过强强联手,晖致医药有限公司成为世界上最大的仿制药制造商之一,为超过 165 个国家提供服务。虽然涵盖 10 多个主要治疗领域,但晖致医药有限公司已将皮肤科、眼科和胃肠科确定为未来创新的三个关键重点领域。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405190012108b15e795&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405190012108b15e795&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VTRS"],"gpt_icon":0},{"id":"2434013062","title":"BUZZ-Viatris 第一季度收入不及预期,业绩下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2434013062","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434013062?lang=zh_cn&edition=full","pubTime":"2024-05-09 22:04","pubTimestamp":1715263445,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) 5月9日 - ** 制药商 Viatris 股价下跌 3.4% 至 11.40 美元 ** 受老药销售疲软影响,该公司第一季度营收略低于 (link) 预期 ** 第一季度营收为36.5亿美元,低于分析师平均预期的36.9亿美元--LSEG数据 ** VTRS 公布第一季度每股副利润为 67 美分,符合预期 ** 占 VTRS 总收入三分之二的品牌药物部门净销售额下降 4.5%,至 23.1 亿美元 ** 包括盘中走势在内,该股今年累计上涨 3.3","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1839511570.USD","BK4583","BK4007","VTRS","LU2087621335.USD","BUZZ","BK4585","BK4588"],"gpt_icon":0},{"id":"2434138220","title":"晖致盘中异动 股价大跌5.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2434138220","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434138220?lang=zh_cn&edition=full","pubTime":"2024-05-09 21:30","pubTimestamp":1715261459,"startTime":"0","endTime":"0","summary":"北京时间2024年05月09日21时30分,晖致股票出现异动,股价大幅下挫5.76%。截至发稿,该股报11.13美元/股,成交量16.9092万股,换手率0.01%,振幅3.47%。晖致股票所在的制药行业中,整体跌幅为0.20%。通过强强联手,晖致医药有限公司成为世界上最大的仿制药制造商之一,为超过 165 个国家提供服务。虽然涵盖 10 多个主要治疗领域,但晖致医药有限公司已将皮肤科、眼科和胃肠科确定为未来创新的三个关键重点领域。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050921305987e86c59&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050921305987e86c59&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VTRS","BK4583","LU2087621335.USD","LU1839511570.USD","BK4588","BK4585","BK4007"],"gpt_icon":0},{"id":"2433316733","title":"Viatris Inc 预计每股收益 67 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2433316733","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433316733?lang=zh_cn&edition=full","pubTime":"2024-05-08 01:36","pubTimestamp":1715103383,"startTime":"0","endTime":"0","summary":" * Viatris Inc 将于5月9日公布截至2024年3月31日的财报,预计该公司的季度收入将出现下降。* 根据LSEG的数据,5位分析师的平均预期显示,这家总部位于宾夕法尼亚州卡农斯堡的公司预计营收将从去年同期的37.3亿美元下降1.0%,至36.91亿美元。* LSEG 分析师对 Viatris Inc 的平均预期为每股收益 67 美分。* 华尔街对 Viatris Inc 的 12 个月目标价中位数为 12.50 美元,高于其最新收盘价 11.82 美元。5月7日 - 以前季度业绩。除非另有说明,所有数字均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTRS"],"gpt_icon":0},{"id":"2425591658","title":"英国 Theramex 公司认为 CMA 调查不会影响 HRT 产品供应","url":"https://stock-news.laohu8.com/highlight/detail?id=2425591658","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2425591658?lang=zh_cn&edition=full","pubTime":"2024-04-06 01:39","pubTimestamp":1712338758,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) 路透社4月5日 - Theramex周五表示,该公司正在考虑英国竞争监督机构对该公司购买美国制药商Viatris 的两个妇女保健产品系列的欧洲权利进行的第一阶段调查所提出的问题。该公司在给路透社的一份声明中说,监管机构的决定是兼并审查过程中的正常步骤,不会影响其在英国供应现有激素替代疗法(HRT) 产品的能力。竞争与市场管理局(CMA) 前一天曾表示, (link),由于Theramex是英国HRT市场最大的供应商之一,该交易可能导致HRT价格上涨和选择减少。监管机构称,在对该交易进行第二阶段调查之前,双方有五个工作日的时间做出回应。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4207","CMA","VTRS","BK4211","BK4585","BK4007","BK4588","LU1839511570.USD","BK4130","HRT","BK4583","LU2087621335.USD","BK4589"],"gpt_icon":0},{"id":"2424836139","title":"英国监管机构称 Theramex-Viatris 交易引发竞争问题","url":"https://stock-news.laohu8.com/highlight/detail?id=2424836139","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2424836139?lang=zh_cn&edition=full","pubTime":"2024-04-04 18:22","pubTimestamp":1712226130,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) 路透社4月4日 - 英国竞争监督机构称,Theramex公司购买Viatris公司 两个妇女保健产品系列的欧洲权利可能会导致激素替代疗法的价格上涨和选择减少。 制药商Viatris同意 (link),于10月份将其Duphaston和Femoston系列产品的销售权出售给总部位于伦敦的Theramex公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTRS","BK4585","BK4007","BK4588","LU1839511570.USD","BK4583","LU2087621335.USD"],"gpt_icon":0},{"id":"2422141524","title":"BUZZ-杰富瑞认为澳大利亚 CSL 公司每股收益下降","url":"https://stock-news.laohu8.com/highlight/detail?id=2422141524","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2422141524?lang=zh_cn&edition=full","pubTime":"2024-03-26 02:32","pubTimestamp":1711391569,"startTime":"0","endTime":"0","summary":" 3月25日 - ** Jefferies 分析师认为,CSL Vifor 将受到 Viatris 可能于 24 财年下半年在美国市场推出仿制 Venofer 的影响。** 券商维持 CSL 338.50 澳元/股的目标价和 \"买入 \"评级** 杰富瑞预计CSL Vifor在美国销售Venofer活性药物成分的分销商利润率将低于在欧盟销售该产品的利润率。** 券商认为 CSL 26 财年的每股收益将下降 0.8** 16位分析师中有11位将该股评为 \"买入 \"或更高评级,4位评为 \"持有\",1位评为 \"卖出\";他们的PT中值为310.00澳元--LSEG数据** 截至上次收盘,该股今年下跌了 1","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7511","CSL.AU","BK4588","LU1839511570.USD","LU2087621335.USD","VTRS","BK4007","BK7501","BK4583","BK7067","BK4585"],"gpt_icon":0},{"id":"2418391850","title":"嗡嗡声--美国股票走势-Acelyrin、Endeavour Silver、B2Gold","url":"https://stock-news.laohu8.com/highlight/detail?id=2418391850","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2418391850?lang=zh_cn&edition=full","pubTime":"2024-03-12 02:18","pubTimestamp":1710181116,"startTime":"0","endTime":"0","summary":" * 个股异动的 Eikon 搜索字符串:[STXBZ] * The Day Ahead 新闻通讯: * The Morning News Call时事通讯: 3月11日 - 华尔街主要股指周一下滑,投资者在等待本周的关键通胀数据,在上周喜忧参半的就业报告之后,这些数据可能为美国联邦储备局的货币政策路径提供线索。美东时间14:02,道琼斯工业平均指数 上涨0.05%,报38,742.57点。标准普尔500指数 下跌0.16%,报5,115.28点;纳斯达克综合指数 下跌0.32%,报16,033.175点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXRX","RYDE","NQmain","SCX",".DJI","PSQ","MNQmain","EXK","NRIX","QQQ","SQQQ","BILI","09618",".SPX","DDM","DJX","WBD","NFG","09988","FTRE","QID","SDOW","ETRN","PARA",".IXIC","BABA","DXD","EQT","VTRS","H","UDOW","DHCAU","PDD","SLRN","TQQQ","XPDB","STI","EOLS","AMPY","JD","TISI","MRNA","QLD","BTG","ML","LBBB","AMD","CHRO","DOG","BA"],"gpt_icon":0},{"id":"2418330118","title":"美国 FDA 拒绝批准 Viatris 用于治疗多发性硬化症的注射剂","url":"https://stock-news.laohu8.com/highlight/detail?id=2418330118","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2418330118?lang=zh_cn&edition=full","pubTime":"2024-03-11 19:06","pubTimestamp":1710155165,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) 路透社3月11日 - Viatris 和Mapi Pharma两家公司周一表示,美国食品及药物管理局已拒绝批准Viatris 和Mapi Pharma用于治疗复发性多发性硬化症的每月一次注射剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU1839511570.USD","BK4583","BK4585","LU2087621335.USD","VTRS","BK4588"],"gpt_icon":0},{"id":"2416909272","title":"Viatris Inc.2023财年实现净利润54.70百万美元,同比减少97.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2416909272","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2416909272?lang=zh_cn&edition=full","pubTime":"2024-03-04 00:22","pubTimestamp":1709482964,"startTime":"0","endTime":"0","summary":"12月31日,Viatris Inc.公布财报,公告显示公司2023财年净利润为54.70百万美元,同比减少97.37%;其中营业收入为153.82亿美元,同比减少4.90%,每股基本收益为0.05美元。从资产负债表来看,Viatris Inc.总负债272.18亿美元,其中短期债务20.26亿美元,资产负债比为1.76,流动比率为1.58。机构评级:截至2023年12月31日,当前有7家机构对Viatris Inc.目标价做出预测,其中目标均价为11.67美元,其中最低目标价为10.00美元,最高目标价为14.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403040022538afdd686&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403040022538afdd686&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VTRS"],"gpt_icon":0},{"id":"2415517304","title":"嗡嗡声--美国股票走势-Shift4 Payments、Chart Industries、Applied Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2415517304","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2415517304?lang=zh_cn&edition=full","pubTime":"2024-02-29 03:26","pubTimestamp":1709148400,"startTime":"0","endTime":"0","summary":" * Eikon 个股走势搜索字符串:[STXBZ] * The Day Ahead 新闻通讯: * The Morning News Call时事通讯: 2月28日 - 华尔街主要股指周三下滑,因本周晚些时候的通胀数据将影响人们对美国联邦储备委员会何时开始降息的预期。美东时间13:38,道琼斯工业平均指数 下跌0.10%,报38933.98点。标准普尔500指数 下跌0.05%,报5075.46点;纳斯达克综合指数 下跌0.36%,报15976.84点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FLYW","UNH","SCCO","QLD","QQQ","AVDX","IE0009355771.USD","DDM","INGN","NEE","RIOT","NQmain","TREE","FOUR","MARA","NVAX","ABSI","SHOO","DOG","EBAY","COCO",".IXIC","SDOW","BYND","MNQmain",".DJI","LU1839511570.USD","TQQQ","QID","IXHL","PAYO","PDD","AMAT","VTNR","BROS","URBN","BMBL","LU0370786039.SGD","DJX","VANI","VTRS","PDCO","PSQ","AXON","SQQQ",".SPX","UDOW","AMBA","LMND","DXD"],"gpt_icon":0},{"id":"2415796372","title":"Viatris Inc盘中异动 临近午盘急速下挫5.06%报12.56美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2415796372","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2415796372?lang=zh_cn&edition=full","pubTime":"2024-02-29 00:47","pubTimestamp":1709138878,"startTime":"0","endTime":"0","summary":"北京时间2024年02月29日00时47分,Viatris Inc股票出现异动,股价大幅下跌5.06%。截至发稿,该股报12.56美元/股,成交量1054.05万股,换手率0.88%,振幅7.29%。Viatris Inc股票所在的制药行业中,整体跌幅为1.13%。Viatris Inc公司简介:晖致医药有限公司成立于2020年11月,由专门生产专利到期药物的辉瑞全资子公司 Upjohn 和专注于仿制药和专科药物的全球制药制造商 Mylan 合并而成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022900475879159278&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022900475879159278&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","VTRS","LU2087621335.USD","BK4588","BK4583","BK4585","LU1839511570.USD"],"gpt_icon":0},{"id":"2414326199","title":"BUZZ-Viatris 因第四季度业绩疲软而下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2414326199","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2414326199?lang=zh_cn&edition=full","pubTime":"2024-02-28 21:08","pubTimestamp":1709125690,"startTime":"0","endTime":"0","summary":" 2月28日 - ** Viatris 股价在盘前交易中下跌2%,报12.95美元** 该公司公布第四季度销售额为38.3亿美元,略低于分析师预计的38.7亿美元--LSEG数据 ** VTRS 季度净亏损为 7.656 亿美元,去年同期为净利润 10.1 亿美元,受运营费用增加的影响。** 该公司还预计 2024 年的利润介于每股 2.70 美元至 2.85 美元之间,低于预期中点的每股 2.81 美元。** 截至上次收盘,VTRS 今年迄今已上涨 22.2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BUZZ","BK4588","BK4007","BK4585","VTRS","LU2087621335.USD","BK4583","LU1839511570.USD"],"gpt_icon":0},{"id":"2414840018","title":"Viatris Inc 预计每股收益 65 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2414840018","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2414840018?lang=zh_cn&edition=full","pubTime":"2024-02-26 21:43","pubTimestamp":1708955038,"startTime":"0","endTime":"0","summary":" * Viatris Inc 将于2月28日公布截至2023年12月31日的财报,预计季度收入将有所增长。* 根据LSEG的数据,6位分析师的平均预期显示,这家总部位于宾夕法尼亚州卡农斯堡的公司预计营收将从去年同期的38.7亿美元增至38.7亿美元,增幅为0.1%。) * LSEG 分析师对 Viatris Inc 的平均预期为每股收益 65 美分。* 华尔街对 Viatris Inc 的 12 个月目标价中位数为 11.00 美元,低于其最新收盘价 13.53 美元。2月26日 - 上一季度业绩。除非另有说明,所有数字均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTRS"],"gpt_icon":0},{"id":"2411270541","title":"Viatris Inc盘中异动 早盘股价大涨5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2411270541","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2411270541?lang=zh_cn&edition=full","pubTime":"2024-02-15 22:55","pubTimestamp":1708008936,"startTime":"0","endTime":"0","summary":"北京时间2024年02月15日22时55分,Viatris Inc股票出现波动,股价快速上涨5.10%。Viatris Inc股票所在的制药行业中,整体涨幅为0.23%。其相关个股中,Cardiol Therapeutics Inc、Organon & Co、Durect Corp涨幅较大,苏轩堂、Sunshine Biopharma Inc、Petros Pharmaceuticals Inc较为活跃,换手率分别为18.57%、10.83%、10.55%,振幅较大的相关个股有Cardiol Therapeutics Inc、Durect Corp、Alimera Sciences Inc,振幅分别为18.99%、12.69%、9.88%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024021522553687e70355&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024021522553687e70355&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4583","LU1839511570.USD","BK4588","BK4585","LU2087621335.USD","VTRS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.viatris.com","stockEarnings":[{"period":"1week","weight":0.0534},{"period":"1month","weight":0.1781},{"period":"3month","weight":0.0524},{"period":"6month","weight":0.0386},{"period":"1year","weight":0.1309},{"period":"ytd","weight":0.0933}],"compareEarnings":[{"period":"1week","weight":-0.0196},{"period":"1month","weight":0.0009},{"period":"3month","weight":0.1087},{"period":"6month","weight":0.138},{"period":"1year","weight":0.2141},{"period":"ytd","weight":0.155}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Viatris Inc.于2019年2月14日在特拉华州成立。该公司是一家全球性的医疗保健公司,该公司认为他们具有独特的定位,可以弥合仿制药和品牌之间的传统鸿沟,将两者的优点结合起来,以更全面地满足全球范围内的医疗保健需求。Viatris的使命是赋能世界各地的人们在生命的每个阶段都能过上更健康的生活,它大规模地提供准入服务,目前每年为全球约10亿患者提供高质量的药物,并触及生命的所有时刻,从出生到生命的尽头,从急性病到慢性病。","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.048097},{"month":2,"riseRate":0.25,"avgChangeRate":-0.100502},{"month":3,"riseRate":0,"avgChangeRate":-0.065492},{"month":4,"riseRate":0,"avgChangeRate":-0.039911},{"month":5,"riseRate":0.5,"avgChangeRate":0.057634},{"month":6,"riseRate":0.5,"avgChangeRate":-0.028874},{"month":7,"riseRate":0.5,"avgChangeRate":0.019761},{"month":8,"riseRate":0.666667,"avgChangeRate":0.015415},{"month":9,"riseRate":0,"avgChangeRate":-0.088155},{"month":10,"riseRate":0.333333,"avgChangeRate":0.025615},{"month":11,"riseRate":0.666667,"avgChangeRate":0.014134},{"month":12,"riseRate":1,"avgChangeRate":0.100515}],"exchange":"NASDAQ","name":"Viatris Inc.","nameEN":"Viatris Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Viatris Inc.(VTRS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Viatris Inc.(VTRS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Viatris Inc.,VTRS,Viatris Inc.股票,Viatris Inc.股票老虎,Viatris Inc.股票老虎国际,Viatris Inc.行情,Viatris Inc.股票行情,Viatris Inc.股价,Viatris Inc.股市,Viatris Inc.股票价格,Viatris Inc.股票交易,Viatris Inc.股票购买,Viatris Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Viatris Inc.(VTRS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Viatris Inc.(VTRS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}